Table 3.
Logistic regression analysis for predictors of NIH lung response
| Univariable |
Multivariable |
||||||||
|---|---|---|---|---|---|---|---|---|---|
| Clinical variable | OR | 95% CI | P value | OR | 95% CI | P value | |||
| Belumosudil dose | 200 mg QD vs 200 mg BID | 1.67 | 0.49 | 5.62 | .41 | ||||
| 400 mg QD vs 200 mg BID | 1.42 | 0.27 | 7.52 | .68 | |||||
| Age | <50 vs ≥50 | 0.90 | 0.30 | 2.69 | .85 | ||||
| Sex | Male vs female | 7.22 | 1.81 | 28.8 | .005 | 14.07 | 2.36 | 83.70 | .0037 |
| HLA donor match | Partially matched vs matched | 2.31 | 0.42 | 12.7 | .34 | ||||
| Response to last systemic therapy | PR vs no PR | 4.36 | 1.11 | 17.2 | .036 | 7.89 | 1.31 | 47.71 | .024 |
| Conditioning intensity | MAC vs NMA | 3.14 | 0.62 | 16.0 | .17 | ||||
| NIH severity at enrollment | Moderate vs severe | 3.23 | 0.84 | 12.40 | .088 | 2.80 | 0.50 | 15.79 | .24 |
| Number of organs involved at enrollment | ≥4 vs <4 | 1.68 | 0.50 | 5.61 | .4 | ||||
| NIH lung score at enrollment | 1 vs (2 or 3) | 5.67 | 1.63 | 19.70 | .006 | 5.65 | 1.35 | 29.60 | .028 |
| Time from cGVHD to enrollment in months | <24 vs ≥24 | 0.73 | 0.24 | 2.19 | .57 | ||||
| <36 vs ≥36 | 1.35 | 0.44 | 4.13 | .6 | |||||
BID, twice daily; MAC, myeloablative conditioning; NMA, nonmyeloablative; OR, odds ratio; QD, daily